Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2004-03-26
2008-09-16
Campell, Bruce (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C424S184100, C536S023100
Reexamination Certificate
active
07425611
ABSTRACT:
Described herein are nucleic acid molecules which encode multiple highly conserved epitopes from HIV-1 proteins, and optionally also epitopes from CCR5; usually also included sequences that encode spacers between two or more of the epitopes. Some of the provided nucleic acid molecules further include sequences that encode targeting domains, useful for targeting the encoded protein into a pathway for enhancing epitope presentation in a vertebrate immune system. Also described are multivalent proteins encoded for by these nucleic acid molecules. The disclosure also encompasses immunogenic compositions that comprise one or more of the nucleic acid molecules, and/or one or more of the proteins encoded thereby, as well as methods of inducing an immune response against HIV-1 in a subject by administering to the subject an effective amount of a composition containing one or more of these molecules. Also provided are cultured host cells containing within them one or more of the described nucleic acid molecules.
REFERENCES:
patent: 5633234 (1997-05-01), August et al.
patent: 6319503 (2001-11-01), Kenten et al.
patent: 6534482 (2003-03-01), Fikes et al.
patent: 2002/0119127 (2002-08-01), Sette et al.
patent: 2002/0182222 (2002-12-01), Groot
patent: 2003/0003440 (2003-01-01), Lopalco
patent: 2003/0108562 (2003-06-01), Hanke et al.
patent: 1 130 289 (2001-09-01), None
patent: WO 99/58658 (1999-11-01), None
patent: WO 00/29008 (2000-05-01), None
patent: WO 01/12216 (2001-02-01), None
patent: WO 01/19408 (2001-03-01), None
patent: WO 01/24810 (2001-04-01), None
patent: WO 01/47955 (2001-07-01), None
patent: WO 02/36806 (2002-05-01), None
patent: WO 02/080851 (2002-10-01), None
patent: WO 03/029285 (2003-04-01), None
patent: WO 03/097675 (2003-11-01), None
Duarte et al., Multiepitope polypeptide of the HIV-1 envelope induces neutralizing monoclonal antibodies against V3 loop, 1994, AIDS Research and Human Retroviruses, 10(3): 235-243.
Carbone et al., The Use of Hydrophobic, a Helix-Defined Peptides in Delineating the T cell Determinant for Pigeon Cytochrome c, Journal of Immunology, 1987, 138(6):1838-1844.
Suhrbier et al., Polytope vaccines for the codelivery of multiple CD8 T-cell epitopes, Expert Rev. Vaccines, 2002, 1(2):207-213.
Velders et al., Defined Flanking Spacers and Enhanced Proteolysis Is Essential for Eradication of Established Tumors by an Epitope String DNA Vaccine, The Journal of Immunology, 2001, 166: 5366-5373.
Amara et al., “Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine,”Science292:69-74 (Apr. 6, 2001).
Bonini et al., “Targeting Antigen in Mature Dendritic Cells for Simultaneous Stimulation of CD4+and CD8+T Cells,”J. Immunology166:5250-5257 (2001).
Boyer et al., “HIV-1 DNA based vaccine induces a CD8 meidated cross-clade CTL response,”Dev Biol Stand95:147-153 (1998) Abstract Only.
Fredericksen et al., “Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus,”J Virology72(22):11440-11446 (Nov. 2002) Abstract Only.
Fujita et al., “In vitro binding study of adaptor protein complex (AP-1) to lysosomal targeting motif (LI-motif),”Biochem Biophys Res Commun255(1):54-58 (Feb. 1999) Abstract Only.
Hanke and McMichael, “Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya,”Nature Medicine6(9):951-955 (Sep. 2000).
Keating et al. “Cross-clade T lymphocyte-mediated immunity to HIV type 1: implications for vaccine design and immunodetection assays,”AIDS Res Hum Retroviruses18(14):1067-1079 (Sep. 20, 2000) Abstract Only.
Kong Wing-Pui et al, “Immunogenicity of Multiple gene and clade human immunodeficiency virus type 1 DNA vaccines,”J Virology77(23):12764-12772 (Dec. 2003).
Lacaille et al., “Targeting of HIV-1 Nef to the Centrosome: Implications for Antigen Processing,”Traffic1:884-891 (2000).
Lacasse et al., “Fusion-competent vaccines: Broad neutralization of primary isolates of HIV,”Science283(5400):357-362 (Jan. 15, 1999).
Livingston et al., “Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines,”Vaccine19:4652-4660 (2001).
Lohnas et al., “Epitope-Specific Antibody and Suppression of Autoantibody Responses Against a Hybrid Self Protein,”J. Immunology161:6518-6525 (1998).
Lu, “HIV-1 Gag DNA Vaccine Chimera with Expression and Adjuvant Properties of the Lysosomal-Associated Membrane Protein (LAMP) and Dendritic Cell Multi-Lectin Receptor (DC-MLR) in an AAV-ITR Plasmid Vector,”Aids Vaccine Conference AbstractURL: http://63.84.172.40/Posters/312.1.pdf> (Sep. 7, 2001).
Owen et al., “Susceptibility of diverse primary HIV isolates with varying co-receptor specificity's to CXCR4 antagonistic compounds,”J. Medical Virology68(2):147-155 (Oct. 2002).
Ruff et al., “The Enhanced Immune Response to the HIV gp160/LAMP Chimeric Gene Product Targeted to the Lysosome Membrane Protein Trafficking Pathway,”J. Biological Chemistry272(13):8671-8678 (1997).
Singh et al., “Generation of genome-wide CD8 T cell responses in HLA-A*0201 transgenic mice by an HIV-1 ubiquitin expression library immunization vaccine,”J Immunology168(1)379-391 (Jan. 1, 2002).
Suhrbier, “Multi-epitope DNA vaccines,”Immunol Cell Biol75(4):402-408 (1997) Abstract Only.
Sykes and Johnston, “Genetic live vaccines mimic the antigenicity but not pathogenicity of live viruses,”DNA Cell Biol18(7):521-531 (Jul. 1999).
Thomson et al., “Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination,”J. Immunology160:1717-1723 (1998).
Thomson et al., “Targeting a Polyepitope Protein Incorporating Multiple Class II-Restricted Viral Epitopes to the Secretory/Endocytic Pathway Facilitates Immune Recognition by CD4+Cytotoxic T Lymphocytes: a Novel Approach to Vaccine Design,”J. Virology72(3):2246-2252 (Mar. 1998).
Tobery et al., “Targeting of HIV-1 Antigens for Rapid Intracellular Degradation Enhances Cytotoxic T Lymphocyte (CTL) Recognition and the Induction of De Novo CTL Responses In Vivo After Immunization,”J Exp Med185(5):909-920 (Mar. 3, 1997).
Tourdot et al., “Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class 1 KO mice,”Eur J Immunol31(10):3064-3074 (Oct. 2001) Abstract Only.
Rowell et al., “Lysosome-Associated Membrane Protein-1-Mediated Targeting of the HIV-1 Envelope Protein to an Endosomal/Lysosomal Compartment Enhances its Presentation to MHC Class II-Restricted T Cells,”J Immunology155:1818-1828 (1995).
Woodberry et al., “Immunogenicity of a Human Immunodeficiency Virus (HIV) Polytope Vaccine Containing Multiple HLA A2 HIV CD8+Cytotoxic T-Cell Epitopes,”J Virology73(7):5320-5325 (Jul. 1999).
Lal Renu B.
Owen Sherry M.
Campell Bruce
Kinsey White Nicole
Klarquist & Sparkman, LLP
The United States of America as represented by the Secretary of
LandOfFree
Immunogenic HIV-1 multi-clade, multivalent constructs and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic HIV-1 multi-clade, multivalent constructs and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic HIV-1 multi-clade, multivalent constructs and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3986011